Bristol-Myers Squibb registers observational study of first-line Reblozyl in lower-risk MDS
New non-interventional trial will track luspatercept use and outcomes in German patients with transfusion-dependent lower-risk myelodysplastic neoplasms.
This week brought one new registry entry for Bristol-Myers Squibb.
- A new observational study, "LUNIS" (NCT07752121), will follow adult patients in Germany with documented myelodysplastic neoplasms classified as very low, low, or intermediate risk under IPSS-R criteria, who require at least 2 units of red blood cells within 8 weeks before starting treatment1. The study is not yet recruiting, with an estimated start date of August 24, 2026, and plans to enroll 190 participants1. Its primary outcome is the percentage of participants achieving red blood cell transfusion independence for at least 8 consecutive weeks, measured up to Week 241.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.